JP2014528700A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528700A5
JP2014528700A5 JP2014521695A JP2014521695A JP2014528700A5 JP 2014528700 A5 JP2014528700 A5 JP 2014528700A5 JP 2014521695 A JP2014521695 A JP 2014521695A JP 2014521695 A JP2014521695 A JP 2014521695A JP 2014528700 A5 JP2014528700 A5 JP 2014528700A5
Authority
JP
Japan
Prior art keywords
inhibitor
composition
composition according
seq
stranded rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014521695A
Other languages
English (en)
Japanese (ja)
Other versions
JP6313203B2 (ja
JP2014528700A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/046928 external-priority patent/WO2013012806A2/en
Publication of JP2014528700A publication Critical patent/JP2014528700A/ja
Publication of JP2014528700A5 publication Critical patent/JP2014528700A5/ja
Application granted granted Critical
Publication of JP6313203B2 publication Critical patent/JP6313203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014521695A 2011-07-18 2012-07-16 Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤 Active JP6313203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161508867P 2011-07-18 2011-07-18
US61/508,867 2011-07-18
US201161543038P 2011-10-04 2011-10-04
US61/543,038 2011-10-04
PCT/US2012/046928 WO2013012806A2 (en) 2011-07-18 2012-07-16 Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells

Publications (3)

Publication Number Publication Date
JP2014528700A JP2014528700A (ja) 2014-10-30
JP2014528700A5 true JP2014528700A5 (cg-RX-API-DMAC7.html) 2015-08-20
JP6313203B2 JP6313203B2 (ja) 2018-04-18

Family

ID=47558691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521695A Active JP6313203B2 (ja) 2011-07-18 2012-07-16 Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤

Country Status (9)

Country Link
US (1) US9453226B2 (cg-RX-API-DMAC7.html)
EP (2) EP2734240B1 (cg-RX-API-DMAC7.html)
JP (1) JP6313203B2 (cg-RX-API-DMAC7.html)
CN (1) CN103889461B (cg-RX-API-DMAC7.html)
AU (1) AU2012284223B2 (cg-RX-API-DMAC7.html)
CA (2) CA3205596A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907620T3 (cg-RX-API-DMAC7.html)
PT (1) PT3366302T (cg-RX-API-DMAC7.html)
WO (1) WO2013012806A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
ES2732929T3 (es) 2010-10-22 2019-11-26 Olix Pharmaceuticals Inc Moléculas de ácido nucleico que inducen interferencia de ARN y usos de las mismas
US9707235B1 (en) * 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
WO2013169382A1 (en) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Methods and devices for treating intervertebral disc disease
EP3514236A1 (en) 2012-05-22 2019-07-24 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
WO2014039696A2 (en) 2012-09-05 2014-03-13 Cold Spring Harbor Laboratory Transposable elements, tdp-43, and neurodegenerative disorders
EP2968613B1 (en) 2013-03-11 2019-09-11 University of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
US9326983B2 (en) 2013-08-01 2016-05-03 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
WO2015095609A1 (en) * 2013-12-19 2015-06-25 The J. David Gladstone Institute Inhibition of interferon-gamma-inducible protein 16 (ifi16)
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
WO2015138628A1 (en) * 2014-03-11 2015-09-17 University Of Florida Research Foundation, Inc. Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
WO2016022914A1 (en) * 2014-08-08 2016-02-11 Moderna Therapeutics, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
ES2879678T3 (es) 2015-02-26 2021-11-22 Univ Kentucky Res Found Composiciones y procedimientos para el tratamiento de la degradación retiniana
US11219623B2 (en) 2015-02-26 2022-01-11 University Of Kentucky Research Foundation Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis
CA2997516C (en) 2015-09-03 2024-02-06 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Analogues of vdac1-derived peptides
EP3373939A4 (en) * 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University MEDIUM AND METHOD FOR REDUCING TUMORIGENITY OF CANCER STEM CELLS
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
WO2017212477A1 (en) * 2016-06-07 2017-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Backbone cyclized inhibitory peptides of myeloid differentiation factor 88 (myd88)
US11130951B2 (en) * 2016-06-09 2021-09-28 The General Hospital Corporation Modulating the cellular stress response
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
US20190185820A1 (en) * 2016-08-26 2019-06-20 The Regents Of The University Of California Compositions and Methods for Inhibiting Stem Cell Aging
ES2950100T3 (es) 2016-12-23 2023-10-05 Casp Aid Inc Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas
JP7424728B2 (ja) 2017-02-10 2024-01-30 オリック パルマセゥティカルズ インコーポレイテッド Ｒｎａ干渉のための長鎖の二本鎖ｒｎａ
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
US11613756B2 (en) * 2017-04-03 2023-03-28 Duke University Compositions and methods for differential induction of cell death and interferon expression
US20200345756A1 (en) * 2017-10-10 2020-11-05 University Of Virginia Patent Foundation Compositions and methods for treating age-related macular degeneration and geographic atrophy
CN112512515B (zh) * 2018-06-27 2025-10-10 儿童医学中心公司 用于抑制炎症的化合物
KR102138256B1 (ko) * 2018-09-13 2020-08-13 한국과학기술연구원 케스페이즈-1 활성 측정용 프로브, 이를 포함하는 염증성 질환 진단용 조성물
US20210348164A1 (en) * 2018-10-09 2021-11-11 University Of Virginia Patent Foundation Endogenous cytoplasmic alu complementary dna in age-related macular degeneration
CN110305957B (zh) * 2019-08-22 2022-07-29 中国水产科学研究院淡水渔业研究中心 一种鉴定黄颡鱼脂肪肝程度的试剂盒及其鉴定方法
CN114599373A (zh) * 2019-08-23 2022-06-07 弗吉尼亚大学专利基金会 靶向炎性疾病的ddx17和nlrc4
JP7459298B2 (ja) * 2020-01-06 2024-04-01 シーサン・セラピューティクス 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物
WO2021163327A1 (en) * 2020-02-11 2021-08-19 University Of Virginia Patent Foundation Compositions and methods for treating and/or preventing ocular disorders
CN111358950A (zh) * 2020-03-20 2020-07-03 厦门大学 Caspase-1及ASC/Caspase-8作为靶点的应用
US20240011030A1 (en) * 2020-08-10 2024-01-11 Novartis Ag Treatments for retinal degenerative diseases
TW202233237A (zh) 2020-11-18 2022-09-01 瑞士商諾華公司 用於在治療ｎｌｒｃ４－ｇｏｆ炎性體病變中使用的雙特異性抗體
CN114099683B (zh) * 2021-12-28 2022-12-16 首都医科大学附属北京同仁医院 Nox2特异性抑制剂在制备视网膜变性药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
WO2000047218A1 (en) * 1999-02-11 2000-08-17 The Trustees Of The University Of Pennsylvania Regulation of photoreceptor degeneration
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US20030186903A1 (en) * 2001-11-23 2003-10-02 Isis Pharmaceuticals Inc. Antisense modulation of MyD88 expression
EP1474444A1 (en) * 2002-01-10 2004-11-10 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A novel splice variant of myd88 and uses thereof
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
BRPI0519148A2 (pt) 2004-12-20 2008-12-30 Sigma Tau Ind Farmaceuti inibidores de homodimerizaÇço de myd88
US7879992B2 (en) * 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
WO2008070579A2 (en) 2006-12-01 2008-06-12 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
AU2008260572A1 (en) * 2007-05-29 2008-12-11 Yale University IL- 18 and protein kinase R inhibition for the treatment of COPD
US20090227487A1 (en) * 2008-03-05 2009-09-10 Jeremy Pearl Methods for the control of macrophage-associated inflammation
JP2011530293A (ja) * 2008-08-08 2011-12-22 イデラ ファーマシューティカルズ インコーポレイテッド アンチセンスオリゴヌクレオチドによる骨髄細胞分化初期応答遺伝子８８（ｍｙｄ８８）発現の調節
US20130137642A1 (en) * 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2011153234A2 (en) 2010-06-01 2011-12-08 University Of Kentucky Research Foundation Methods of inhibiting alu rna and therapeutic uses thereof
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment

Similar Documents

Publication Publication Date Title
JP2014528700A5 (cg-RX-API-DMAC7.html)
JP2013536015A5 (cg-RX-API-DMAC7.html)
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
WO2007059342A3 (en) Random copolymer compositions for treating unwanted immune response
JP2016508134A5 (cg-RX-API-DMAC7.html)
JP2014532654A5 (cg-RX-API-DMAC7.html)
HRP20120264T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe
US9415046B2 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
WO2015138628A8 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
JP2016539125A5 (cg-RX-API-DMAC7.html)
JP2015526467A5 (cg-RX-API-DMAC7.html)
JP2016027060A5 (cg-RX-API-DMAC7.html)
JP2018530574A5 (cg-RX-API-DMAC7.html)
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
Hajishengallis et al. Complement-targeted therapeutics in periodontitis
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
CN108350458B (zh) 用豹蛙酶和/或两栖酶治疗病毒性结膜炎
JP2020533302A5 (cg-RX-API-DMAC7.html)
JP2020513033A5 (cg-RX-API-DMAC7.html)
WO2005120542A3 (en) Methods of treating disease with random copolymers
JP2016505050A5 (cg-RX-API-DMAC7.html)
RU2019101226A (ru) Ингибиторы wnt для применения при лечении фиброза
JP2011500589A5 (cg-RX-API-DMAC7.html)
JP2016512247A5 (cg-RX-API-DMAC7.html)
WO2016088797A1 (ja) Ａｌｓの原因タンパク毒性を軽減する核酸